The influence of the prolactin inhibitor bromocriptin (CB 154) on human luteal function in vivo.
Five volunteers with normal ovarian cycles received oral doses of 2 X 2.5 mg or 3 X 2.5 mg bromocriptin (CB 154)/day respectively. The treatment started at the onset of menstruation and lasted on complete cycle. In addition to the decrease of prolactin secretion, a reduction of plasma progesterone concentrations during the corpus luteum phase was demonstrated. This fall of progesterone seemed to be preferentially due to bromocriptin-induced hypoprolactinaemia and not to direct ovarian effects of the drug.
D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology*; D003338:Corpus Luteum / Q000187:drug effects*; D004873:Ergolines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008598:Menstruation; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000037:antagonists & inhibitors* / Q000097:blood; D013997:Time Factors
D004873:Ergolines; D001971:Bromocriptine; D011374:Progesterone; D011388:Prolactin